Insider Selling: Privia Health Group (NASDAQ:PRVA) CFO Sells $119,847.55 in Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 5,177 shares of the company’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $23.15, for a total value of $119,847.55. Following the sale, the chief financial officer owned 167,732 shares in the company, valued at $3,882,995.80. The trade was a 2.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

David Mountcastle also recently made the following trade(s):

• On Monday, March 9th, David Mountcastle sold 5,829 shares of Privia Health Group stock. The shares were sold at an average price of $22.84, for a total value of $133,134.36.
• On Thursday, February 26th, David Mountcastle sold 5,361 shares of Privia Health Group stock. The shares were sold at an average price of $25.00, for a total value of $134,025.00.
• On Friday, February 27th, David Mountcastle sold 7,697 shares of Privia Health Group stock. The stock was sold at an average price of $25.05, for a total value of $192,809.85.
• On Friday, December 12th, David Mountcastle sold 23,887 shares of Privia Health Group stock. The stock was sold at an average price of $25.03, for a total value of $597,891.61.

Privia Health Group Trading Down 1.5%

NASDAQ PRVA opened at $21.73 on Friday. The company has a market cap of $2.69 billion, a PE ratio of 127.82, a PEG ratio of 1.39 and a beta of 0.82. Privia Health Group, Inc. has a 12 month low of $18.77 and a 12 month high of $26.51. The stock has a 50 day moving average of $22.93 and a 200-day moving average of $23.58.

Privia Health Group (NASDAQ:PRVA) last released its earnings results on Thursday, February 26th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.21. The business had revenue of $541.17 million during the quarter, compared to analysts’ expectations of $516.61 million. Privia Health Group had a net margin of 1.08% and a return on equity of 3.06%. The firm’s revenue was up 17.4% on a year-over-year basis. During the same period last year, the business earned $0.21 earnings per share. As a group, sell-side analysts predict that Privia Health Group, Inc. will post 0.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on PRVA shares. Truist Financial boosted their price objective on shares of Privia Health Group from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Wolfe Research set a $31.00 target price on shares of Privia Health Group in a research note on Tuesday, January 6th. BMO Capital Markets began coverage on Privia Health Group in a report on Thursday, November 13th. They set an “outperform” rating and a $30.00 price target for the company. Canaccord Genuity Group boosted their price target on Privia Health Group from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Finally, Piper Sandler restated an “overweight” rating and issued a $36.00 price objective on shares of Privia Health Group in a research note on Thursday, February 26th. Thirteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.00.

Hedge Funds Weigh In On Privia Health Group

Several large investors have recently modified their holdings of PRVA. Van Berkom & Associates Inc. lifted its stake in shares of Privia Health Group by 30.1% during the 3rd quarter. Van Berkom & Associates Inc. now owns 3,774,565 shares of the company’s stock worth $93,987,000 after buying an additional 873,344 shares during the last quarter. Vanguard Group Inc. grew its stake in Privia Health Group by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 12,098,933 shares of the company’s stock valued at $301,263,000 after buying an additional 607,447 shares during the last quarter. ArrowMark Colorado Holdings LLC grew its stake in Privia Health Group by 139.4% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 841,266 shares of the company’s stock valued at $19,946,000 after buying an additional 489,866 shares during the last quarter. Algert Global LLC raised its holdings in Privia Health Group by 277.4% in the 3rd quarter. Algert Global LLC now owns 484,304 shares of the company’s stock valued at $12,059,000 after acquiring an additional 355,966 shares during the period. Finally, Freestone Grove Partners LP raised its holdings in Privia Health Group by 40.6% in the 4th quarter. Freestone Grove Partners LP now owns 1,213,342 shares of the company’s stock valued at $28,768,000 after acquiring an additional 350,194 shares during the period. 94.48% of the stock is owned by institutional investors.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.